Your session is about to expire
← Back to Search
Cardiac MRI for Tricuspid Regurgitation
N/A
Waitlist Available
Led By Mohamad Alkhouli, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial assesses the severity of tricuspid regurgitation with cardiac MRI.
Who is the study for?
This trial is for individuals with moderate or severe tricuspid regurgitation, which is when the heart's tricuspid valve doesn't close properly. Participants must not have a pacemaker/defibrillator that interferes with MRI, any prior tricuspid valve replacements, planned surgery on the tricuspid valve, or primary liver disease.
What is being tested?
The study aims to evaluate how well cardiac magnetic resonance imaging (MRI) can determine the severity of tricuspid regurgitation in patients' hearts.
What are the potential side effects?
Cardiac MRI is generally safe; however, some may experience discomfort from lying still during the procedure. There are no significant side effects associated directly with this non-invasive imaging technique.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of Severity of tricuspid regurgitation by cardiac magnetic resonance imaging
Secondary study objectives
Correlation between severity of Tricuspid regurgitation by cardiac magnetic resonance imaging vs. elastography
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Moderate or severe tricuspid regurgitationExperimental Treatment1 Intervention
40 patients with moderate or more TR on echocardiography will undergo CMR/MRE with contrast to assess TR severity, and the associated extra-valvular cardiac and liver abnormalities. Patients will continue their clinical management by their primary physicians as per the standards of care. 1-year follow up will be conducted via phone to inquire about patient's vital status (dead/alive), symptoms and hospitalizations.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cardiac Magnetic Resonance
2018
N/A
~150
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,362 Previous Clinical Trials
3,065,886 Total Patients Enrolled
Mohamad Alkhouli, MDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
475 Total Patients Enrolled